Teladoc Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Teladoc Health, Inc. on September 9, 2024. The report discloses the appointment of a new senior executive officer effective as of the filing date.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the appointment of Joseph Catapano as Senior Vice President and Chief Accounting Officer, effective September 9, 2024. Mr. Catapano previously served as Vice President and Chief Accounting Officer at Pitney Bowes Inc.
Management Commentary and Compensation Details
Mr. Catapano's executive employment agreement includes the following compensation terms:
- Base Salary: $375,000 annually.
- Sign-on Bonus: $100,000.
- Annual Bonus: Targeted at 40% of base salary, with a guaranteed 2024 bonus of $150,000.
- Equity Award: 25,000 restricted stock units (RSUs). Vesting is scheduled as one-third on the first anniversary of the grant date, with the remainder vesting in eight quarterly installments starting on the 15-month anniversary.
Mr. Catapano is eligible for severance under the Company's Level 13 Severance Plan and is subject to standard non-compete and non-solicitation provisions for one year post-termination.
Investor Verification Checklist
- Verify the impact of the new Chief Accounting Officer on the company's financial reporting processes and internal controls.
- Review the total cost of the new executive compensation package relative to the company's current cash position and burn rate.
- Confirm the vesting schedule and potential dilution impact of the 25,000 RSU grant.
- Check for any subsequent filings regarding the departure of the previous Chief Accounting Officer or Controller.